The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | Amyloidosis: patient fitness determines therapeutic strategies
Giampaolo Merlini, MD from Scientific Institute Policlinico San Matteo, University of Pavia, Pavia, Italy provides an overview of amyloidosis treatment for different subsets of patients depending on levels of ‘fitness’. He outlines different modes of therapy including stem cell transplantation, chemotherapy and combined therapy including pomalidomide and dexamethasone which shows promising results. Recorded at the European Hematological Association (EHA) 2017 in Madrid, Spain.
